Rania S Sulaiman1,2,3,4, Judith Quigley1,2, Xiaoping Qi1,2, Michael N O'Hare1,2,5, Maria B Grant1,2, Michael E Boulton1,2, Timothy W Corson1,2,3,6,7. 1. 1 Eugene and Marilyn Glick Eye Institute, Indiana University School of Medicine , Indianapolis, Indiana. 2. 2 Department of Ophthalmology, Indiana University School of Medicine , Indianapolis, Indiana. 3. 3 Department of Pharmacology and Toxicology, Indiana University School of Medicine , Indianapolis, Indiana. 4. 4 Department of Biochemistry, Faculty of Pharmacy, Cairo University , Cairo, Egypt . 5. 5 School of Biomedical Science, University of Ulster , Coleraine, Northern Ireland, United Kingdom . 6. 6 Department of Biochemistry and Molecular Biology, Indiana University School of Medicine , Indianapolis, Indiana. 7. 7 Indiana University Melvin and Bren Simon Cancer Center , Indianapolis, Indiana.
Abstract
PURPOSE: Therapeutic efficacy is routinely assessed by measurement of lesion size using flatmounted choroids and confocal microscopy in the laser-induced choroidal neovascularization (L-CNV) rodent model. We investigated whether optical coherence tomography (OCT) quantification, using an ellipsoid volume measurement, was comparable to standard ex vivo evaluation methods for this model and whether this approach could be used to monitor treatment-related lesion changes. METHODS: Bruch's membrane was ruptured by argon laser in the dilated eyes of C57BL/6J mice, followed by intravitreal injections of anti-VEGF164 or vehicle, or no injection. In vivo OCT images were acquired using Micron III or InVivoVue systems at 7, 10, and/or 14 days post-laser and neovascular lesion volume was calculated as an ellipsoid. Subsequently, lesion volume was compared to that calculated from confocal Z-stack images of agglutinin-stained choroidal flatmounts. RESULTS: Ellipsoid volume measurement of orthogonal 2-dimensional OCT images obtained from different imaging systems correlated with ex vivo lesion volumes for L-CNV (Spearman's ρ=0.82, 0.75, and 0.82 at days 7, 10, and 14, respectively). Ellipsoid volume calculation allowed temporal monitoring and evaluation of CNV lesions in response to antivascular endothelial growth factor treatment. CONCLUSIONS: Ellipsoid volume measurements allow rapid, quantitative use of OCT for the assessment of CNV lesions in vivo. This novel method can be used with different OCT imaging systems with sensitivity to distinguish between treatment conditions. It may serve as a useful adjunct to the standard ex vivo confocal quantification, to assess therapeutic efficacy in preclinical models of CNV, and in models of other ocular diseases.
PURPOSE: Therapeutic efficacy is routinely assessed by measurement of lesion size using flatmounted choroids and confocal microscopy in the laser-induced choroidal neovascularization (L-CNV) rodent model. We investigated whether optical coherence tomography (OCT) quantification, using an ellipsoid volume measurement, was comparable to standard ex vivo evaluation methods for this model and whether this approach could be used to monitor treatment-related lesion changes. METHODS: Bruch's membrane was ruptured by argon laser in the dilated eyes of C57BL/6J mice, followed by intravitreal injections of anti-VEGF164 or vehicle, or no injection. In vivo OCT images were acquired using Micron III or InVivoVue systems at 7, 10, and/or 14 days post-laser and neovascular lesion volume was calculated as an ellipsoid. Subsequently, lesion volume was compared to that calculated from confocal Z-stack images of agglutinin-stained choroidal flatmounts. RESULTS: Ellipsoid volume measurement of orthogonal 2-dimensional OCT images obtained from different imaging systems correlated with ex vivo lesion volumes for L-CNV (Spearman's ρ=0.82, 0.75, and 0.82 at days 7, 10, and 14, respectively). Ellipsoid volume calculation allowed temporal monitoring and evaluation of CNV lesions in response to antivascular endothelial growth factor treatment. CONCLUSIONS: Ellipsoid volume measurements allow rapid, quantitative use of OCT for the assessment of CNV lesions in vivo. This novel method can be used with different OCT imaging systems with sensitivity to distinguish between treatment conditions. It may serve as a useful adjunct to the standard ex vivo confocal quantification, to assess therapeutic efficacy in preclinical models of CNV, and in models of other ocular diseases.
Authors: Yali Jia; Steven T Bailey; David J Wilson; Ou Tan; Michael L Klein; Christina J Flaxel; Benjamin Potsaid; Jonathan J Liu; Chen D Lu; Martin F Kraus; James G Fujimoto; David Huang Journal: Ophthalmology Date: 2014-03-27 Impact factor: 12.079
Authors: Magdalena G Krzystolik; Mehran A Afshari; Anthony P Adamis; Jacques Gaudreault; Evangelos S Gragoudas; Norman A Michaud; Wenjun Li; Edward Connolly; Charles A O'Neill; Joan W Miller Journal: Arch Ophthalmol Date: 2002-03
Authors: Michael O'Hare; Mehdi Shadmand; Rania S Sulaiman; Kamakshi Sishtla; Toshiaki Sakisaka; Timothy W Corson Journal: Int J Cancer Date: 2016-06-24 Impact factor: 7.396
Authors: Manas R Biswal; Howard M Prentice; George W Smith; Ping Zhu; Yao Tong; C Kathleen Dorey; Alfred S Lewin; Janet C Blanks Journal: J Mol Med (Berl) Date: 2018-08-13 Impact factor: 4.599
Authors: Yaqian Duan; Eleni Beli; Sergio Li Calzi; Judith L Quigley; Rehae C Miller; Leni Moldovan; Dongni Feng; Tatiana E Salazar; Sugata Hazra; Jude Al-Sabah; Kakarla V Chalam; Thao Le Phuong Trinh; Marya Meroueh; Troy A Markel; Matthew C Murray; Ruchi J Vyas; Michael E Boulton; Patricia Parsons-Wingerter; Gavin Y Oudit; Alexander G Obukhov; Maria B Grant Journal: Stem Cells Date: 2018-07-15 Impact factor: 6.277
Authors: Mei Chen; Jiangping Hou; Guilin Tan; Peng Xie; William R Freeman; James R Beadle; Karl Y Hostetler; Lingyun Cheng Journal: Drug Deliv Date: 2017-11 Impact factor: 6.419